(3,5-Di-p-tolyl-oxazolo[3,4-c]oxazol-7a-yl)-methanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,5-Di-p-tolyl-oxazolo[3,4-c]oxazol-7a-yl)-methanol
• 英文别名: [3,5-bis(4-methylphenyl)-1,3,5,7-tetrahydro-[1,3]oxazolo[3,4-c][1,3]oxazol-7a-yl]methanol
• 化学式: C₂₀H₂₃NO₃
• mdl: MFCD01595311
• 分子量: 325.4
• InChiKey: ZTDOUYKICCDXMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Neuroprotective agents
  申请人：Michaelis Louise Mary

  公开号：US20070099971A1

  公开（公告）日：2007-05-03

  Novel stereoisomers of GS-164 are provided. The compounds, such as (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol (TH-237A) and (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol (TH-242A) exhibit neuroprotective effects via a mechanism that does not involve microtubule stabilization.

  提供了GS-164的新立体异构体。这些化合物，例如(3R,5S,7as)-(3,5-双(4-氟苯基)四氢-1H-噁唑并[3,4-c]噁唑-7a-基)甲醇(TH-237A)和(3R,5S,7as)-(3,5-双(4-氟苯基)四氢-1H-噁唑并[3,4-c]噁唑-7a-基)甲醇(TH-242A)，通过一种不涉及微管稳定的机制表现出神经保护作用。
• PRODRUGS OF (3,5-BIS(4-FLUOROPHENYL)TETRAHYDRO-1H-OXAZOLO[3,4-C]OXAZOL-7A-YL)METHANOL AND DERIVATIVES THEREOF
  申请人：Rajewski Roger A.

  公开号：US20100056592A1

  公开（公告）日：2010-03-04

  A prodrug that has a prodrug moiety that degrades into a compound having the general Formula I with R3 being an alcoholic moiety can be useful in therapies for neurodegenerative diseases as well as cancer. Accordingly, the prodrug compounds can have a structure of Formula I, analogs thereof, derivatives thereof, or salts thereof, wherein: A and B are sulfur or oxygen; R1 and R2, in para, meta, or ortho position, are independently halogen, alkyl, alkoxy, haloalkyl, where R1 and R2 independently are straight chain, branched, substituted or unsubstituted; and R3 is a prodrug moiety. As examples, the prodrug can have a structure of any of Formulas I-V, which as shown in the specification.

  具有可降解为具有一般式I的化合物的前药基团的前药可以用于神经退行性疾病以及癌症的治疗。因此，前药化合物可以具有I式、其类似物、衍生物或盐的结构，其中：A和B是硫或氧；R1和R2在对、间或邻位独立地是卤素、烷基、烷氧基、卤代烷基，其中R1和R2独立地是直链、支链、取代或未取代的；而R3是前药基团。例如，前药可以具有任何I-V式的结构，如规范中所示。
• US7598282B2
  申请人：——

  公开号：US7598282B2

  公开（公告）日：2009-10-06
• US8318787B2
  申请人：——

  公开号：US8318787B2

  公开（公告）日：2012-11-27
• [EN] NEUROPROTECTIVE AGENTS<br/>[FR] AGENTS NEUROPROTECTEURS
  申请人：UNIV KANSAS

  公开号：WO2007053684A2

  公开（公告）日：2007-05-10

  [EN] Novel stereoisomers of GS-164 are provided. The compounds, such as (3R,5S,7as)- (3,5-bis(4-fluoro?henyl)tetrahydro-lH'-oxazolo[3,4-c]oxazol-7a-yl)methanol (TH-237A) and (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-lH-oxazolo[3,4-c]oxazol-7a-yl)methanol (TH- 242A) exhibit neuroprotective effects via a mechanism that does not involve microtubule stabilization.
  [FR] La présente invention concerne de nouveaux stéréoisomères de GS-164. Les composés, tels que le (3R,5S,7as)-(3,5-bis(4-fluorophényl)tétrahydro-1H'-oxazolo[3,4-c]oxazol-7a-yl)méthanol (TH-237A) et le (3R,5S,7as)-(3,5-bis(4-fluorophényl)tétrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)méthanol (TH-242A), présentent des effets neuroprotecteurs via un mécanisme qui n'implique pas la stabilisation des microtubules.